Joseph Chattahi, MD
Cardiovascular Disease · Dearborn, MINPI 1780893214
Payments from drug & device makers
Across 181 payments — averaging $111.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kestra Medical Technology Services, Inc.$6K
- ZOLL Circulation Inc$4K
- Edwards Lifesciences$3K
- Boston Scientific$2K
- Abiomed$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$888
- plus $4K from 30 others
Across 1 payment — averaging $134.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$135
What the payments were for
- Consulting fees$4,00020%
- Speaking & faculty fees$6,60033%
- Travel & lodging$9655%
- Food & beverage$8,46142%
- Education$1801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kestra Medical Technology Services, Inc. | 17 | $5,569 |
| ZOLL Circulation Inc | 10 | $4,463 |
| Edwards Lifesciences | 38 | $2,637 |
| Boston Scientific | 16 | $1,793 |
| Abiomed | 11 | $1,244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $888 |
| Abbott | 8 | $607 |
| AstraZeneca | 8 | $241 |
| Avinger Inc. | 4 | $236 |
| Daiichi Sankyo Inc. | 2 | $229 |
| Amgen | 2 | $221 |
| Novartis | 6 | $208 |
| Cardiva Medical, Inc. | 4 | $183 |
| Astellas Pharma US Inc | 2 | $180 |
| Cathworks, Inc. | 1 | $169 |
| Philips North America LLC | 4 | $155 |
| Johnson & Johnson | 8 | $147 |
| GE HealthCare | 1 | $130 |
| Pharmacosmos Therapeutics Inc. | 1 | $124 |
| AMAG Pharmaceuticals, Inc. | 1 | $108 |
| Lilly USA, LLC | 1 | $106 |
| Truvic Medical, Inc. | 1 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $96 |
| Medtronic | 1 | $73 |
| Heartflow, Inc. | 2 | $51 |
| Novo Nordisk | 2 | $43 |
| Teleflex LLC | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Shockwave Medical, Inc | 1 | $25 |
| Pfizer | 1 | $19 |
| Angiodynamics, Inc. | 1 | $18 |
| Cordis US CORP. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Aegerion Pharmaceuticals, Inc. | 1 | $13 |
| Cardinal Health 200 LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assure WCD$5,246
- TherOx DS2 Console$4,257
- Catheter$4,257
- Downstream Cartridge$4,257
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,798
- Impella$937
- SAPIEN 3 Ultra RESILIA$261
- LifeVest$234
- PANTHERIS$226
- OPTIS$175
- FFRangio$169
- COROFLOW$162
- INJECTAFER$129
- Watchman$125
- ENTRESTO$125
- Cardiva VASCADE MVP VVCS 6-12F$125
- Monoferric$124
- Repatha$114
- FERAHEME$108
- AMPLATZER Occluders$107
How this compares
$20,206 in reported general payments places this provider in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 396 | $429,762 |
| EntrestoSacubitril/Valsartan | 152 | $169,111 |
| XareltoRivaroxaban | 77 | $83,716 |
| BrilintaTicagrelor | 79 | $53,477 |
| MultaqDronedarone Hcl | 14 | $20,479 |
| Repatha SureclickEvolocumab | 23 | $14,253 |
| Metoprolol Succinate | 756 | $11,641 |
| ClopidogrelClopidogrel Bisulfate | 364 | $4,796 |
| Atorvastatin Calcium | 460 | $4,773 |
| Matzim LaDiltiazem Hcl | 16 | $4,471 |
| Losartan Potassium | 360 | $4,208 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 129 | $3,056 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 158 | $3,042 |
| Amlodipine Besylate | 343 | $2,641 |
| Carvedilol | 235 | $2,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $429,762396 claims |
| NovartisEntresto | $208 | $169,111152 claims |
| Johnson & JohnsonXarelto | $147 | $83,71677 claims |
| AstraZenecaBrilinta | $241 | $53,47779 claims |
| Sanofi-aventis U.S. LLCMultaq | $96 | $20,47914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Elias KassabDearborn$352K
- Sohail HassanDearborn$296K
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.